Key result
The novel FLNC-Ile1937Asn variant caused a severe form of hypertrophic cardiomyopathy, with end-stage heart failure requiring transplantation in 43% and sudden cardiac death in 29% of carriers.
Why the study?
Data on the clinical course of FLNC-related HCM are conflicting, with some studies suggesting mild phenotypes and others reporting more severe outcomes.
Observational
The novel FLNC-Ile1937Asn variant causes a highly penetrant, severe form of hypertrophic cardiomyopathy with a high risk of end-stage heart failure and sudden cardiac death.
May warrant heightened surveillance in FLNC-HCM families; leaves open broader applicability pending validation studies.
Variants of filamin C (FLNC) have been identified as rare genetic substrate for hypertrophic cardiomyopathy (HCM). Data on the clinical course of FLNC-related HCM are conflicting with some studies suggesting mild phenotypes whereas other studies have reported more severe outcomes. In this study, we present a novel FLNC variant (Ile1937Asn) that was identified in a large family of French-Canadian descent with excellent segregation data. FLNC-Ile1937Asn is a novel missense variant characterized by full penetrance and poor clinical outcomes. End stage heart failure requiring transplantation occurred in 43% and sudden cardiac death in 29% of affected family members. Other particular features of FLNC-Ile1937Asn include an early disease onset (mean age of 19 years) and the development of a marked atrial myopathy (severe biatrial dilatation with remodeling and multiple complex atrial arrhythmias) that was present in all gene carriers. The FLNC-Ile1937Asn variant is a novel, pathogenic mutation resulting in a severe form of HCM with full disease penetrance. The variant is associated with a high proportion of end-stage heart failure, heart transplantation, and disease-related mortality. Close follow-up and appropriate risk stratification of affected individuals at specialized heart centers is recommended.
No takes yet. Share an insight, caveat, or question.
Gaudreault et al. (2023) conducted an observational in Hypertrophic cardiomyopathy (HCM). FLNC-Ile1937Asn variant was evaluated on End stage heart failure requiring transplantation. The novel FLNC-Ile1937Asn variant caused a severe form of hypertrophic cardiomyopathy, with end-stage heart failure requiring transplantation in 43% and sudden cardiac death in 29% of carriers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: